Core Insights - The article compares Royal Philips (PHG) and EssilorLuxottica Unsponsored ADR (ESLOY) to determine which stock offers better value opportunities for investors [1] Valuation Metrics - Both PHG and ESLOY hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and improving earnings outlooks [3] - PHG has a forward P/E ratio of 19.66, while ESLOY has a forward P/E of 30.93, suggesting that PHG may be undervalued compared to ESLOY [5] - The PEG ratio for PHG is 1.02, indicating a more favorable valuation relative to its expected earnings growth, whereas ESLOY has a PEG ratio of 3.43 [5] - PHG's P/B ratio is 2.26, compared to ESLOY's P/B of 2.48, further supporting the notion that PHG is the more attractive value option [6] - Based on these valuation figures, PHG is considered the superior value option at this time [7]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Develo ...

Core Viewpoint - The article highlights Koninklijke Philips (PHG) as a strong value investment opportunity, showcasing its favorable valuation metrics compared to industry averages [4][5][6][7]. Valuation Metrics - PHG has a Zacks Rank of 2 (Buy) and an A for Value, indicating strong potential for value investors [4]. - The stock's P/E ratio is 18.09, significantly lower than the industry average of 22.20 [4]. - PHG's Forward P/E has fluctuated between 12.29 and 18.27 over the past 12 months, with a median of 14.35 [4]. - The PEG ratio for PHG is 0.94, compared to the industry's average PEG of 2.18, suggesting it is undervalued relative to its expected earnings growth [5]. - Over the past 52 weeks, PHG's PEG has ranged from 0.78 to 1.33, with a median of 0.92 [5]. - The P/B ratio for PHG is 2.26, which is attractive compared to the industry average of 5.35 [6]. - PHG's P/B has varied between 1.28 and 2.28 over the past 12 months, with a median of 1.58 [6]. Investment Outlook - The combination of these valuation metrics indicates that Koninklijke Philips is likely undervalued, making it one of the strongest value stocks in the market [7].

Core Insights - The collaboration between Royal Philips and Jackson Health System reveals significant sustainability benefits from transitioning to Philips' next-generation monitoring solutions, including a 47% reduction in carbon emissions and substantial cost savings [1][2][3] Group 1: Sustainability Impact - The Life Cycle Assessment (LCA) indicates that Philips patient monitors can reduce carbon emissions by 685.1 tons of CO2e, which is a 47% decrease compared to previous systems [1][2] - The transition eliminates the need for approximately 420,000 disposable AA batteries and 6.5 million sheets of paper, leading to an estimated savings of $1.2 million over a 10-year device lifetime [1][2] - Philips IntelliVue and EarlyVue monitors contribute to a reduction of 508 tons of CO2e across all lifecycle facets, with additional savings from battery and paper reductions amounting to 177.1 tons [2] Group 2: Operational Efficiency - The previous telemetry monitors required hundreds of disposable AA battery replacements weekly and involved manual paper processes, while Philips monitors utilize rechargeable batteries and automate workflows, reducing waste and allowing clinicians to focus more on patient care [2] - Jackson Health System has implemented sustainable procurement practices, including trading in legacy monitors for refurbishment and recycling, promoting circularity and minimizing landfill waste [3] Group 3: Industry Leadership - Jackson Health System is recognized for its commitment to sustainable practices that enhance both human and environmental health, balancing advanced technology needs with sustainability [3] - Philips North America emphasizes the importance of integrating advanced technology to reduce carbon emissions and waste, which can improve staff satisfaction and productivity while enhancing patient care [4]

Enhanced longer version of Philips LumiGuide Navigation Wire enables US clinicians to visualize a broader range of catheters Internationally recognized vascular surgeon Carlos Timaran, MD, was the first to use the new LumiGuide wire to perform a complex aortic repair, Procedure marks the world's 1000th procedure assisted by Philips' unique Fiber Optic RealShape (FORS) guidance technology Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced ...

Core Viewpoint - Investors in the Medical - Products sector should consider Royal Philips (PHG) and EssilorLuxottica Unsponsored ADR (ESLOY) for potential value opportunities, with PHG currently showing stronger value metrics [1]. Group 1: Zacks Rank and Earnings Outlook - Royal Philips has a Zacks Rank of 2 (Buy), indicating a favorable earnings outlook, while EssilorLuxottica has a Zacks Rank of 4 (Sell), suggesting a weaker earnings outlook [3]. - The improvement in earnings outlook for PHG is stronger compared to ESLOY, making it a more attractive option for value investors [3]. Group 2: Valuation Metrics - PHG has a forward P/E ratio of 20.10, significantly lower than ESLOY's forward P/E of 31.46, indicating that PHG may be undervalued relative to ESLOY [5]. - The PEG ratio for PHG is 1.04, while ESLOY's PEG ratio is 3.49, further suggesting that PHG offers better value considering expected earnings growth [5]. - PHG's P/B ratio stands at 2.21, compared to ESLOY's P/B of 2.49, reinforcing the notion that PHG is a more favorable investment based on valuation metrics [6]. Group 3: Overall Value Grades - PHG has a Value grade of A, while ESLOY has a Value grade of D, indicating that PHG is perceived as a superior value option based on various financial metrics [6].

Core Insights - Philips has renewed its partnership with Isala hospital to enhance healthcare delivery through innovative and cost-effective solutions [1] - The company is expanding its customer base with new collaborations, including a 10-year strategic partnership with Nicklaus Children's Health System and a partnership with Bon Secours Mercy Health [4][5] - Philips' shares have increased by 26.4% year-to-date, significantly outperforming the industry growth of 6.2% [3] Customer Base Expansion - Isala hospital will replace medical systems like MRI and CT scanners with Philips' technology, ensuring continuous updates and sustainability [2] - Philips has partnered with 14 major hospitals in Spain to utilize its ambulatory cardiac monitoring service for detecting Atrial Fibrillation [6] - A technology agreement with Dutch Franciscus Gasthuis & Vlietland hospital aims to develop a future-proof operating suite using Philips' Azurion platform [7] Portfolio Strength - Philips is enhancing its portfolio with new products like the Image Guided Therapy Mobile C-arm System 9000 and Zenition 90 Motorized, aimed at improving clinician productivity [8] - The launch of an AI-enabled cardiovascular ultrasound platform has received FDA 510(k) clearance, enhancing the Precision Diagnosis portfolio [9] - HealthSuite Imaging, an AI-enabled cloud-based system, has been introduced to improve operational efficiency and patient care [10] Financial Performance Expectations - For 2024, Philips anticipates a comparable sales growth of 3-5% [10] - The Zacks Consensus Estimate for 2024 revenues is projected at $19.99 billion, indicating a year-over-year growth of 1.7% [11] - The consensus for 2024 earnings is set at $1.50 per share, reflecting an 11.1% increase from the previous year [12]

August 5, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase shares for an amount of up to EUR 125 million to cover certain of its obligations arising from its long-term incentive plans. At the current share price, this represents a total of approximately 4.8 million shares. The repurchases will be executed through a combination of forward transactions and open market purchases with a financial institution. Philips expects to take delivery of the f ...

August 5, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase shares for an amount of up to EUR 125 million to cover certain of its obligations arising from its long-term incentive plans. At the current share price, this represents a total of approximately 4.8 million shares. The repurchases will be executed through a combination of forward transactions and open market purchases with a financial institution. Philips expects to take delivery of the f ...

Forward-looking statements and other important information Important information These factors include but are not limited to: Philips' ability to gain leadership in health informatics in response to developments in the health technology industry; Philips' ability to keep pace with the changing health technology environment; macroeconomic and geopolitical changes; integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining Philips' intellectual ...